Inhalation Sciences (ISAB): 2020 outlook
(Stockholm Jan 27, 2020) Inhalation Sciences’ CEO Manoush Masarrat is looking forward to an eventful year ahead for ISAB, with its world-leading in vitro tool DissolvIt reaching full commercialization, new CRO projects, ongoing clinical validation of PreciseInhale, a packed event schedule and new faces joining the lab. “2020 is going to a very busy year” says Masarrat.After four months as CEO of ISAB and 10 months on its Board, Manoush Masarrat is now firmly behind the wheel. He expects the company to shift up a gear as it accelerates into what he believes could be a pivotal year. “